Showing results (1981-1990 of 2,488) with videos related to

Sort By:
Pageof 249
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 9, 2021
Low lysophosphatidylcholine induces skeletal muscle myopathy that is aggravated by high-fat diet feedingPatrick J Ferrara, Anthony R P Verkerke, J Alan Maschek, et al.
Frontiers in Microbiology|September 21, 2018
Interfering With DNA Decondensation as a Strategy Against MycobacteriaEnzo M Scutigliani, Edwin R Scholl, Anita E Grootemaat, et al.
BMC Genomics|January 13, 2010
Effort required to finish shotgun-generated genome sequences differs significantly among vertebratesRobert W Blakesley, Nancy F Hansen, Jyoti Gupta, et al.
Cancer Medicine|June 20, 2024
Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advancesAlex K Bryant, Rafael Zamora-Resendiz, Xin Dai, et al.
American Journal of Human Genetics|April 12, 2003
Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type VAnthony Antonellis, Rachel E Ellsworth, Nyamkhishig Sambuughin, et al.
Nucleic Acids Research|April 24, 2009
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbersMayumi Oda, Jacob L Glass, Reid F Thompson, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2001
Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitorsK J Wilson, C R Illig, N Subasinghe, et al.
Plos Biology|March 26, 2013
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survivalDaniel Thomas, Jason A Powell, Benjamin D Green, et al.
Cancer Medicine|November 7, 2024
Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare SystemSean R Miller, Matthew Schipper, Lars G Fritsche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-upR L Basser, L B To, J P Collins, et al.
Pageof 249